-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-523863-39-00
6
2026-03-05
chronic wounds
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-522754-39-00
6
2026-02-24
Neonatal respiratory distress syndrome
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-520086-31-00
6
2026-01-07
Hypertrophic cardiomyopathy
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-515125-28-00
4
2025-12-08
Non-obstructive hypertrophic cardiomyopathy
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-520132-15-00
11
2025-11-19
Patients undergoing vitrectomy and/or cataract surgery
-
2025-521744-37-00
5
2025-11-17
Mild to moderate major depressive disorder
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2025-521564-35-00
4
2025-11-06
ischemic stroke with intracranial large artery occlusion of the anteri
-
2024-518206-40-00
5
2025-11-03
Severe hypertriglyceridemia (SHTG)
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes